FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Alan Luger

Research Profile

Procedures

Living Beings

Physiology

Activities & Behaviors

Tissue and Organ Procurement

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Christopher F Bryan; Herbert Polesky; Arthur B Eisenbrey; Deborah A Sesok-Pizzini; Alan M Luger; Douglas M Smith; Brian M Susskind
Implications of ABO error rates in proficiency testing for solid organ transplantation.
Christopher F Bryan; Scott B McDonald; Alan M Luger; Charles F Shield; Franz T Winklhofer; A Michael Borkon; Bradley A Warady; Mark I Aeder; Daniel Murillo
Successful renal transplantation despite low levels of donor-specific HLA class I antibody without IVIg or plasmapheresis.
Christopher F Bryan; Kevin M Harrell; Stanley I Mitchell; Bradley A Warady; Mark I Aeder; Alan M Luger; Daniel Murillo; Nicolas A Muruve; Paul W Nelson; Charles F Shield
HLA points assigned in cadaveric kidney allocation should be revisited: an analysis of HLA class II molecularly typed patients and donors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Alan Luger (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2006: Christopher F Bryan; Herbert Polesky; Arthur B Eisenbrey; Deborah A Sesok-Pizzini; Alan M Luger; Douglas M Smith; Brian M Susskind
Implications of ABO error rates in proficiency testing for solid organ transplantation.
Transplantation 2006;82(6):733-6.
2006: Christopher F Bryan; Scott B McDonald; Alan M Luger; Charles F Shield; Franz T Winklhofer; A Michael Borkon; Bradley A Warady; Mark I Aeder; Daniel Murillo
Successful renal transplantation despite low levels of donor-specific HLA class I antibody without IVIg or plasmapheresis.
Clinical transplantation 2006;20(5):563-70.
2003: Christopher F Bryan; Kevin M Harrell; Stanley I Mitchell; Bradley A Warady; Mark I Aeder; Alan M Luger; Daniel Murillo; Nicolas A Muruve; Paul W Nelson; Charles F Shield
HLA points assigned in cadaveric kidney allocation should be revisited: an analysis of HLA class II molecularly typed patients and donors.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2003;3(4):459-64.
2002: Christopher F Bryan; Scott B McDonald; Karen A Baier; Alan M Luger; Mark I Aeder; Daniel Murillo; Nicolas A Muruve; Paul W Nelson; Charles F Shield; Bradley A Warady
Flow cytometry beads rather than the antihuman globulin method should be used to detect HLA Class I IgG antibody (PRA) in cadaveric renal regraft candidates.
Clinical transplantation 2002;16 Suppl 7():15-23.
2001: Nicolas A Muruve; Thomas S Helling; Alan M Luger; J Martinez; Paul W Nelson; GE Pierce; Gilbert Ross; Charles F Shield; Bradley A Warady; Mark I Aeder; Christopher F Bryan
Effect of donor brain-death duration on graft outcome.
Transplantation proceedings 2001;33(6):2980-1.
2001: Christopher F Bryan; Alan M Luger; J Martinez; Nicolas A Muruve; Paul W Nelson; GE Pierce; Gilbert Ross; Charles F Shield; Bradley A Warady; Mark I Aeder; Thomas S Helling
Cold ischemia time: an independent predictor of increased HLA class I antibody production after rejection of a primary cadaveric renal allograft.
Transplantation 2001;71(7):875-9.
2001: Christopher F Bryan; J Martinez; Nicolas A Muruve; Paul W Nelson; GE Pierce; Gilbert Ross; Charles F Shield; Bradley A Warady; Mark I Aeder; Kevin M Harrell; Thomas S Helling; Alan M Luger
IgM antibodies identified by a DTT-ameliorated positive crossmatch do not influence renal graft outcome but the strength of the IgM lymphocytotoxicity is associated with DR phenotype.
Clinical transplantation 2001;15 Suppl 6():28-35.
2000: Nicolas A Muruve; Keith M Steinbecker; Alan M Luger
Are wedge biopsies of cadaveric kidneys obtained at procurement reliable?
Transplantation 2000;69(11):2384-8.
2000: Christopher F Bryan; Charles F Shield; GE Pierce; Bradley A Warady; Mark I Aeder; J Martinez; Alan M Luger; Paul W Nelson; Gilbert Ross; Nicolas A Muruve; Stanley I Mitchell
Successful cadaveric renal transplantation of patients highly sensitized to HLA Class I antigens.
Clinical transplantation 2000;14(1):79-84.
1999: Christopher F Bryan; Charles F Shield; Bradley A Warady; Mark I Aeder; Thomas S Helling; Alan M Luger; J Martinez; Paul W Nelson; GE Pierce; Gilbert Ross; Nicolas A Muruve; E R Thien
Influence of an historically positive crossmatch on cadaveric renal transplantation.
Transplantation proceedings 1999;31(1-2):225-7.
1998: Christopher F Bryan; Karen A Baier; Paul W Nelson; Alan M Luger; J Martinez; GE Pierce; Gilbert Ross; Charles F Shield; Bradley A Warady; Mark I Aeder; Thomas S Helling; Nicolas A Muruve
Long-term graft survival is improved in cadaveric renal retransplantation by flow cytometric crossmatching.
Transplantation 1998;66(12):1827-32.
1998: Christopher F Bryan; Charles F Shield; Paul W Nelson; GE Pierce; Gilbert Ross; Alan M Luger; Bradley A Warady; Thomas S Helling; Mark I Aeder; J Martinez; T M Hughes; M L Beck; Kevin M Harrell
Transplantation rate of the blood group B waiting list is increased by using A2 and A2B kidneys.
Transplantation 1998;66(12):1714-7.
1998: Christopher F Bryan; Stanley I Mitchell; H M Lin; Paul W Nelson; Charles F Shield; Alan M Luger; GE Pierce; Gilbert Ross; Bradley A Warady; Mark I Aeder; Thomas S Helling; M D Landreneau; Kevin M Harrell
Influence of the Rh (D) blood group system on graft survival in renal transplantation.
Transplantation 1998;65(4):588-92.
1998: Paul W Nelson; M D Landreneau; Alan M Luger; GE Pierce; Gilbert Ross; Charles F Shield; Bradley A Warady; Mark I Aeder; Thomas S Helling; T M Hughes; M L Beck; Kevin M Harrell; Christopher F Bryan
Ten-year experience in transplantation of A2 kidneys into B and O recipients.
Transplantation 1998;65(2):256-60.
1996: Christopher F Bryan; Kevin M Harrell; Paul W Nelson; GE Pierce; Gilbert Ross; Charles F Shield; Bradley A Warady; Mark I Aeder; Thomas S Helling; M D Landreneau; Alan M Luger
HLA-DR and DQ typing by polymerase chain reaction using sequence-specific primer mixes reduces the incidence of phenotypic homozygosity (blanks) over serology.
Transplantation 1996;62(12):1819-24.
1996: Paul W Nelson; P Eschliman; C F Shield; Mark I Aeder; Alan M Luger; G E Pierce; Christopher F Bryan
Improved graft survival in cadaveric renal retransplantation by flow crossmatching.
Archives of surgery (Chicago, Ill. : 1960) 1996;131(6):599-603.
1996: Paul W Nelson; T M Hughes; M L Beck; Bradley A Warady; Mark I Aeder; Thomas S Helling; M D Landreneau; Alan M Luger; GE Pierce; Gilbert Ross
Stratification and successful transplantation of patients awaiting ABO-incompatible (A2 into B and O) transplantation by A-isoagglutinin-titer phenogroup.
Transplantation proceedings 1996;28(1):221-3.
1996: Christopher F Bryan; Charles F Shield; Bradley A Warady; Mark I Aeder; M D Landreneau; Alan M Luger; Paul W Nelson; GE Pierce; Gilbert Ross
Allocation of kidneys to Afro-American patients is proportional to wait-list composition.
Transplantation proceedings 1996;28(1):219-20.
1996: Alan M Luger; Christopher F Bryan; B J O'Brien; GE Pierce; Charles F Shield; Bradley A Warady; Mark I Aeder; M D Landreneau; Paul W Nelson; Gilbert Ross
Do African-Americans wait longer for a kidney because of HLA class I antibody specificities and panel-reactive antibody sensitization?
Transplantation proceedings 1996;28(1):157-9.
1996: Christopher F Bryan; G E Tegtmeier; A Polito; W Bayer; GE Pierce; Charles F Shield; Bradley A Warady; Mark I Aeder; A M Borkon; T H Estep; J Forster; M D Landreneau; Alan M Luger; Paul W Nelson; Gilbert Ross
Evaluation of the 3.0 Ortho EIA assay in 385 consecutive cadaveric organ donors.
Transplantation proceedings 1996;28(1):155-6.
1993: Christopher F Bryan; Mark I Aeder; Alan M Luger; Paul W Nelson; GE Pierce; Gilbert Ross; Charles F Shield; Bradley A Warady
Incidence of a positive final antiglobulin (AHG) T-cell crossmatch in patients waiting for cadaveric renal transplantation is not influenced by race of recipient.
Transplantation proceedings 1993;25(6):3273-4.
1993: Christopher F Bryan; Kevin M Harrell; Mark I Aeder; Alan M Luger; Paul W Nelson; GE Pierce; Gilbert Ross; Charles F Shield; Bradley A Warady
Impact of HLA DR typing by polymerase chain reaction amplification with DR beta 1 sequence-specific primers on cadaveric renal allocation.
Transplantation proceedings 1993;25(6):3060-3.
1993: Christopher F Bryan; Mark I Aeder; Thomas S Helling; Alan M Luger; Paul W Nelson; GE Pierce
Clinical relevance of a positive B-cell crossmatch on renal transplantation: a multi-transplant center evaluation.
Transplantation proceedings 1993;25(1 Pt 1):247-50.
1993: Mark I Aeder; Charles F Shield; G E Tegtmeier; W Bayer; Alan M Luger; Paul W Nelson; GE Pierce; A Polito; J C Wilber; P Johnson
Incidence and clinical impact of hepatitis C virus-positive donors in cadaveric transplantation.
Transplantation proceedings 1993;25(1 Pt 2):1469-71.
1992: Christopher F Bryan; Paul W Nelson; Mark I Aeder; M L Beck; Thomas S Helling; T M Hughes; Alan M Luger; GE Pierce; Charles F Shield
Current experience with renal transplantation across the ABO blood group barrier.
Transplantation proceedings 1992;24(6):2527-9.
1992: Christopher F Bryan; Mark I Aeder; Thomas S Helling; Alan M Luger; Paul W Nelson; GE Pierce; Charles F Shield; A Thomas
Influence of race, PRA level, and gender on the incidence of a positive donor-specific preliminary T cell crossmatch.
Transplantation proceedings 1992;24(6):2517-8.
1992: Christopher F Bryan; Mark I Aeder; Thomas S Helling; J Hughes; Alan M Luger; Paul W Nelson; GE Pierce; Charles F Shield; Bradley A Warady
Influence of HLA and race on long-term cadaveric renal transplantation.
Transplantation proceedings 1992;24(6):2451-3.